Ontology highlight
ABSTRACT: Background
The genomic features of cancer cells may confer the metastatic ability of lung adenocarcinoma (LUAD) to metastasize to specific organs. We aimed to identify the differences in genomic alterations between patients with primary LUAD with and without metastases and to elucidate the metastatic biology that may help developing biomarker-directed therapies for advanced or metastatic disease.Methods
A retrospective cohort of 497 patients with LUAD including 388 primary tumors (PR), 53 bone metastases (MT-bone), 30 liver metastases (MT-liver), and 26 brain metastases (MT-brain) was tested for genomic alterations by a next-generation sequencing assay.Results
The EGFR, TP53, TERT, LRP1B, CDKN2A, ERBB2, ALK, and KM
SUBMITTER: Feng A
PROVIDER: S-EPMC9331737 | biostudies-literature | 2022
REPOSITORIES: biostudies-literature